Articles by Ozgur Ozyilkan
95 monarchE: Subgroup Analysis of Adjuvant Abemaciclib + Endocrine Therapy for HR+/HER2−, High-Risk, Early Breast Cancer by Nodal Status
ByJavier Cortés, MD,Stephen R.D. Johnston,Miguel Martin, MD, PhD,Sara M. Tolaney, MD, MPH,Matthew P. Goetz, MD,Hope S. Rugo, MD,Joohyuk Sohn,Ozgur Ozyilkan,Miguel Henriques Abreu,Matthias Zaiss,Karina Maia Vianna,Hanne Melgaard Nielsen,Arlene Chan,Haralambos Kalofonos, MD,Serafin Morales,Belen San Antonio,Maria Munoz Fernandez,Sasha Amdur,Patrick Neven, MD, PhD,Brenda Grimes 102 Imlunestrant (imlu) With or Without Abemaciclib (abema) in Advanced Breast Cancer (ABC): Safety Analyses From the Phase III EMBER-3 Trial
ByJoyce O’Shaughnessy, MD,Francois Clement Bidard,Patrick Neven, MD, PhD,Monica Lis Casalnuovo,Philippe Aftimos,Cristina Saura,Nadia Harbeck, MD, PhD,Lisa A. Carey, MD,Giuseppe Curigliano,J A Garcia-Saenz,Maria Fernandez Abad,Larissa de Paula,Yeon Hee Park,Ozgur Ozyilkan,Maria Munoz,Sabrina Formentini,Emily Barrett,Shanshan Cao,Aarti Chawla,Komal L. Jhaveri
